Post

New research · Ophthalmology
The oncologist · 1w
Randomized trialThe oncologist · 2026

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Adam Brufsky, Yeon Hee Park, François-Clément Bidard … Nicholas Turner
Read paper
OphthalmologyRandomized trial

Camizestrant increased visual side effects versus aromatase inhibitor in advanced breast cancer

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Adam Brufsky … Nicholas Turner
The oncologist · 2026
Background

We report ophthalmological assessments, patient-reported visual symptoms/functioning, and characterization of visual effect AEs from the SERENA-6 study.

Methods

With emerging ESR1 mutations in ctDNA and no radiological progression were randomized 1:1 to switch to camizestrant+CDK4/6i or continue aromatase inhibitor+CDK4/6i.

n = 315 patients
Results

camizestrant patients who had vision side effects, more than with aromatase inhibitor

Camizestrant+CDK4/6i
31.6%
AI+CDK4/6i
16.1%
More results

No changes in visual acuity or ocular structure were observed.

Patient-reported visual effects occurred early (by week 2) and were reversible post-treatment.

More results

The proportion of patients in the camizestrant+CDK4/6i and aromatase inhibitor+CDK4/6i arm reporting short-lived visual effects (<1min) ranged from 60%-67% vs 50%-69%, respectively; visual effects causing no/a low degree of bother: 78%-88% vs 50%-75%, respectively.

During treatment, visual functioning was comparable to baseline and between arms.

“
Conclusion · 1 of 3

If experienced, patient-reported visual effects (including photopsia) with camizestrant+CDK4/6i were short-lived and reversible post-treatment.

Conclusion · 2 of 3

Visual effect AEs with camizestrant+CDK4/6i were mostly mild and did not require treatment discontinuation or ophthalmologic management.

Conclusion · 3 of 3

There was no impact on ocular structure, function, or visual acuity; visual effects had little/no impact on daily functioning.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment